WO2015104292A3 - Compounds for use in treating or preventing cancerous diseases - Google Patents

Compounds for use in treating or preventing cancerous diseases Download PDF

Info

Publication number
WO2015104292A3
WO2015104292A3 PCT/EP2015/050169 EP2015050169W WO2015104292A3 WO 2015104292 A3 WO2015104292 A3 WO 2015104292A3 EP 2015050169 W EP2015050169 W EP 2015050169W WO 2015104292 A3 WO2015104292 A3 WO 2015104292A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
cancerous diseases
preventing cancerous
compounds
neoplasms
Prior art date
Application number
PCT/EP2015/050169
Other languages
French (fr)
Other versions
WO2015104292A2 (en
Inventor
Dimitris STELLAS
Constantin TAMVAKOPOULOS
Apostolos Klinakis
Argiris Efstratiadis
Zoe COURNIA
Original Assignee
Biomedical Research Foundation Of The Academy Of Athens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Research Foundation Of The Academy Of Athens filed Critical Biomedical Research Foundation Of The Academy Of Athens
Publication of WO2015104292A2 publication Critical patent/WO2015104292A2/en
Publication of WO2015104292A3 publication Critical patent/WO2015104292A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to organic small molecule compounds according to formula (I) for use in treating or preventing cancerous diseases in a mammal, to pharmaceutical compositions comprising such a compound, or to pharmaceutical formulations comprising such a compound or such a composition. The present disclosure also relates to methods of treating or preventing cancerous diseases in a mammal, as well as to a method to screen for a potential therapeutic agent effective in the treatment or prevention of neoplasms, and to an assay system that can be used to screen for a potential therapeutic agent effective in the treatment or prevention of said neoplasms.
PCT/EP2015/050169 2014-01-07 2015-01-07 Compounds for use in treating or preventing cancerous diseases WO2015104292A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14150379.7 2014-01-07
EP14150379 2014-01-07

Publications (2)

Publication Number Publication Date
WO2015104292A2 WO2015104292A2 (en) 2015-07-16
WO2015104292A3 true WO2015104292A3 (en) 2016-02-25

Family

ID=49885165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/050169 WO2015104292A2 (en) 2014-01-07 2015-01-07 Compounds for use in treating or preventing cancerous diseases

Country Status (1)

Country Link
WO (1) WO2015104292A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056230A (en) * 2015-08-03 2015-11-18 中国医学科学院医学生物学研究所 Application of beta-lapachone, and beta-lapachone containing compound adjuvant and vaccine

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035116A1 (en) * 2015-08-25 2017-03-02 President And Fellows Of Harvard College Methods and compositions relating to the diagnosis and treatment of cancer
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
CN106924251B (en) * 2017-04-17 2019-12-03 中国药科大学 It is a kind of for treating the pharmaceutical composition and its application of glioma
KR101825637B1 (en) 2017-04-26 2018-02-06 한국화학연구원 A pharmaceutical composition for prevention or treatment of cancer and use thereof
EP3668532A4 (en) * 2017-08-19 2021-09-01 Ohio State Innovation Foundation Novel peptide-based cancer imaging agents
EP3820847B1 (en) * 2018-07-09 2022-12-14 The Scripps Research Institute Improved compounds for myc inhibition
WO2021102420A1 (en) * 2019-11-22 2021-05-27 The Regents Of The University Of California Interferon signaling as a cancer biomarker
JP2023506768A (en) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー Compositions and methods for prevention and treatment of hearing loss
AU2021266969A1 (en) * 2020-05-04 2022-12-08 Beyondspring Pharmaceuticals, Inc. Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
CN113234064B (en) * 2021-05-27 2022-03-29 西南医科大学附属中医医院 Tegafur derivative and preparation method and application thereof
WO2022266249A1 (en) * 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. J. BONHAM ET AL: "STAT1:DNA sequence-dependent binding modulation by phosphorylation, protein:protein interactions and small-molecule inhibition", NUCLEIC ACIDS RESEARCH, vol. 41, no. 2, 1 January 2013 (2013-01-01), pages 754 - 763, XP055118281, ISSN: 0305-1048, DOI: 10.1093/nar/gks1085 *
ANKE KIESSLING ET AL: "Selective Inhibition of c-Myc/Max Dimerization by a Pyrazolo[1,5-a]pyrimidine", CHEMMEDCHEM, vol. 2, no. 5, 14 May 2007 (2007-05-14), pages 627 - 630, XP055118564, ISSN: 1860-7179, DOI: 10.1002/cmdc.200600294 *
DALINGER IGOR L ET AL: "Liquid-phase synthesis of combinatorial libraries based on 7-trifluoromethyl-substituted pyrazolo[1,5-a]pyrimidine scaffold", JOURNAL OF COMBINATORIAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 7, no. 2, 1 March 2005 (2005-03-01), pages 236 - 245, XP002494988, ISSN: 1520-4766, [retrieved on 20050211], DOI: 10.1021/CC049855O *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105056230A (en) * 2015-08-03 2015-11-18 中国医学科学院医学生物学研究所 Application of beta-lapachone, and beta-lapachone containing compound adjuvant and vaccine

Also Published As

Publication number Publication date
WO2015104292A2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
MX2022005290A (en) Heterocyclic compounds as immunomodulators.
WO2018226622A8 (en) Compounds for treating huntington's disease
WO2017100726A8 (en) Methods for treating huntington's disease
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201891203A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
CA2871471C (en) Dna-pk inhibitors
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014062720A3 (en) Methods of treating cancer
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015108490A3 (en) Heteroaryl alkyne derivatives and uses thereof
EA201691845A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
MX368903B (en) THERAPEUTIC COMPOUNDS and USES THEREOF.
GEP201706663B (en) Novel composition for nonalcoholic fatty liver disease (nafld
EA201691844A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
CL2014001838A1 (en) Compounds derived from fluormethyl-5,6-dihydro-4h- [1,3] oxazin-2-ylamine, as bace1 inhibitors; its process of obtaining; pharmaceutical composition that contains them; and its use for the therapeutic and / or prophylactic treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cancer, cardiovascular diseases and gastrointestinal diseases, among others.
CN107406464A8 (en) Arginase inhibitor and its therapeutical uses
MX369952B (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX355330B (en) CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF.
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
WO2015033228A3 (en) Compounds and use for treating cancer
MX370586B (en) Imidazolyl tricyclic enones as antioxidant iflammation modulators.
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15700341

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15700341

Country of ref document: EP

Kind code of ref document: A2